Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 4/2024

Open Access 01-04-2024 | Melanoma | Research

Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy

Authors: Lujun Shen, Hongtong Tan, Juan Nie, Yiquan Jiang, Gulijiayina Nuerhashi, Han Qi, Fei Cao, Chunyong Wen, Shuanggang Chen, Tianqi Zhang, Wei Zheng, Peng Liu, Ying Liu, Tao Huang, Dandan Li, Xiaoshi Zhang, Weijun Fan

Published in: Cancer Immunology, Immunotherapy | Issue 4/2024

Login to get access

Abstract

Objectives

In this study, we aimed to examine parameters of cryoablation, tumor characteristics, and their correlations with distant tumor response and survival of liver metastatic melanoma patients receiving cryoablation and PD-1 blockade (cryo-PD-1) combination treatment.

Materials and methods

A retrospective study was conducted among 45 melanoma patients who received combined PD-1 blockade therapy and cryoablation for liver metastasis from 2018 to 2022. Cox regression was utilized to determine the associations between factors and overall survival (OS). Changes in cytokines and immune cell compositions in peripheral blood samples following the combined treatment were investigated, along with their correlations with treatment response.

Results

The mean cycle of cryo-PD-1 combination treatment was 2.2 (range, 1–6), and the 3-month overall response rate (RECIST 1.1 criteria) was 26.7%. Of the 21 patients who failed previous PD-1 blockade therapy after diagnosis of liver metastasis, 4 (19.0%) achieved response within 3 months since combination treatment. The diameter of ablated lesion  ≤ 30 mm, metastatic organs  ≤ 2, and pre-treatment LDH level  ≤ 300 U/L were independent prognostic factors for favorable OS. Further analysis showed patients with intrahepatic tumor size of 15–45 mm, and ablated lesion size of  ≤ 30 mm had significantly higher 3-month response rate (42.9% vs 12.5%; P = 0.022) and survival time (30.5 vs 14.2 months; P = 0.045) than their counterparts. The average increase in NLR among patients with ablated tumor size of  ≤ 3 cm and  > 3 cm were 3.59 ± 5.01 and 7.21 ± 12.57, respectively. The average increase in serum IL-6 levels among patients with ablated tumor size of  ≤ 3 cm and  > 3 cm were 8.62 ± 7.95 pg/ml and 15.40 ± 11.43 pg/ml, respectively.

Conclusion

Size selection of intrahepatic lesions for cryoablation is important in order to achieve abscopal effect and long-term survival among patients with liver metastatic melanoma receiving PD-1 blockade therapy.
Appendix
Available only for authorised users
Literature
1.
Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI (2022) The liver-immunity nexus and cancer immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 28(1):5–12CrossRef
2.
3.
4.
Jansen MC, van Hillegersberg R, Schoots IG, Levi M, Beek JF, Crezee H et al (2010) Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147(5):686–695CrossRefPubMed
5.
Abdo J, Cornell DL, Mittal SK, Agrawal DK (2018) Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers. Front Oncol 8:85CrossRefPubMedPubMedCentral
6.
Shen L, Qi H, Chen S, Cao F, Xie L, Wu Y et al (2020) Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Cancer Immunol Immunother CII 69(9):1713–1724CrossRefPubMed
7.
Lujun S, Ying W, Han Q, Yiquan J, Jietian J, Fei C et al (2022) Inducible regulatory T cell predicts efficacy of PD-1 blockade therapy in melanoma. Adv Ther 5(4):2100098CrossRef
8.
Wu Y, Cao F, Zhou D, Chen S, Qi H, Huang T et al (2022) Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity. Front Immunol 13:930461CrossRefPubMedPubMedCentral
9.
Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14(3):199–208CrossRefPubMed
10.
Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S et al (2019) Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun 10(1):5421CrossRefPubMedPubMedCentral
11.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed
12.
Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z et al (2020) The impact of liver metastasis on anti-PD-1 monoclonal antibody monotherapy in advanced melanoma: analysis of five clinical studies. Front Oncol 10:546604CrossRefPubMedPubMedCentral
13.
Kastelan S, Mrazovac Zimak D, Ivankovic M, Markovic I, Gverovic AA (2022) Liver metastasis in uveal melanoma-treatment options and clinical outcome. Front Biosci 27(2):72CrossRef
14.
Koch EAT, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R et al (2021) Immune checkpoint blockade for metastatic uveal melanoma: patterns of response and survival according to the presence of hepatic and extrahepatic metastasis. Cancers 13(13):33596CrossRef
15.
Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA et al (2017) Liver metastasis and treatment outcome with Anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5(5):417–424CrossRefPubMedPubMedCentral
16.
Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C et al (2021) Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. Eur J Cancer 148:61–75CrossRefPubMed
17.
Yakkala C, Denys A, Kandalaft L, Duran R (2020) Cryoablation and immunotherapy of cancer. Curr Opin Biotechnol 65:60–64CrossRefPubMed
18.
Urano M, Tanaka C, Sugiyama Y, Miya K, Saji S (2003) Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. Cryobiology 46(3):238–245CrossRefPubMed
19.
Swinton J, Schweitzer AN, Anderson RM (1994) Two signal activation as an explanation of high zone tolerance: a mathematical exploration of the nature of the second signal. J Theor Biol 169(1):23–30CrossRefPubMed
20.
Li W, Wu Z, Meng W, Zhang C, Cheng M, Chen Y et al (2022) Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy. Cytokine 158:155976CrossRefPubMed
21.
Mallardo D, Fordellone M, White A, Ottaviano M, Sparano F, Bailey M et al (2023) CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. J Transl Med 21(1):610CrossRefPubMedPubMedCentral
22.
Mallardo D, Simeone E, Festino L, Tuffanelli M, Vanella V, Trojaniello C et al (2023) IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. J Transl Med 21(1):140CrossRefPubMedPubMedCentral
23.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 21(1):28CrossRefPubMedPubMedCentral
24.
25.
Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N et al (2022) STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610(7931):373–380CrossRefPubMedPubMedCentral
Metadata
Title
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy
Authors
Lujun Shen
Hongtong Tan
Juan Nie
Yiquan Jiang
Gulijiayina Nuerhashi
Han Qi
Fei Cao
Chunyong Wen
Shuanggang Chen
Tianqi Zhang
Wei Zheng
Peng Liu
Ying Liu
Tao Huang
Dandan Li
Xiaoshi Zhang
Weijun Fan
Publication date
01-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 4/2024
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-024-03637-1

Other articles of this Issue 4/2024

Cancer Immunology, Immunotherapy 4/2024 Go to the issue

Research

Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data

Research

Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity

Research

Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China

Research

Neutrophils seeking new neighbors: radiotherapy affects the cellular framework and the spatial organization in a murine breast cancer model

Research

Oct4 activates IL-17A to orchestrate M2 macrophage polarization and cervical cancer metastasis

Research

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits